News for PainChek Limited (PCK.AX)

PainChek Ltd has raised $5.1M in an Entitlement Offer to facilitate expansion of its Adult App and the launch of an Infant App

Gold continues to jump, with rising demand for haven assets following an escalation of tensions in Russia's invasion of Ukraine.

PainChek (ASX:PCK) has applied for Food and Drug Administration (FDA) De Novo approval for its new PainChek Adult App.

PainChek (ASX: PCK) has announced positive outcomes from a US clinical validation study that will allow the company to progress with a Food and Drug

PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.

Jul 30, 2024 / 12:30AM GMTUnidentified Participant Good morning and welcome to PainChek's investor webinar to discuss the company's quality update, which was re

Jul 27, 2023 / 01:00AM GMTUnidentified Participant Thank you for standing by, and welcome to the PainChek investor webinar and Q&A following the company's quart

Mar 22, 2023 / 02:40AM GMTMatt Wright - NWR Communications - IR Hello and welcome back to the NWR Virtual Healthcare Conference. My name is Matt Wright. Next up

After a day of profit taking yesterday, the ASX200 is set to stablilise, with futures tipping a 0.2 per cent rise. US markets traded mostly flat overnight, although the Nasdaq shed 0.4 per cent ahead of US inflation data due to land late tonight our time.

The ASX200 lost more ground than expected, after it became clear interest rates will still likely rise further before the end of this year.

Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

Can Indian pharma stocks cure the recession blues, the lithium stocks UBS loves, and more grim property news.

The ASX200 has closed Tuesday ahead 0.33%. The Emerging Companies index is down 0.1% as Resources and Mining led the gains at home.

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?